Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its fiscal second quarter and six-months ended March 31, 2015 financial results before the U.S. markets open on May 7, 2015. Enanta management will host a conference call at 8:30 a.m. ET to discuss these results and Enanta’s research and development pipeline.
Conference Call and Webcast Information
To participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the conference
call will be available starting at approximately 11:30 a.m. Eastern time
on May 7, 2015, through 11:59 p.m. Eastern time on May 12, 2015 by
dialing (855) 859-2056 from the U.S. or (404) 537-3406 for international
callers. The passcode for both the live call and the replay is 28434645.
A live audio webcast of the call and replay can be accessed by visiting
the “Calendar of Events” section on the “Investors” page of Enanta’s
website at www.enanta.com.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta is
discovering, and in some cases developing, novel inhibitors designed for
use against the hepatitis C virus (HCV). These inhibitors include
members of the direct acting antiviral (DAA) inhibitor classes –
protease (partnered with AbbVie), NS5A, and nucleotide polymerase – as
well as a host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Enanta’s lead protease inhibitor, paritaprevir, is part of
AbbVie’s recently approved HCV treatment regimens. In addition, Enanta
has a preclinical program in non-alcoholic steatohepatitis, or NASH,
which is a condition that results in liver inflammation and damage
caused by a buildup of fat in the liver.
Contacts:
Enanta Pharmaceuticals, Inc.
Carol
Miceli, 617-607-0710
cmiceli@enanta.com